Service Corp International Inc (SCI): Nice earning beat today. Long-term, thi...

Nice earning beat today. Long-term, this should

Mokyo Toe · 2017-10-26T21:04:13.9000000Z

Nice earning beat today. Long-term, this should only keep going up...

Play Episode

7min

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

Gunnison Copper advances Johnson Camp Mine construction, on track for Cathode Production in Q3 2025

Gunnison Copper SVP- Operations Robert Winton joined Steve Darling from Proactive to provide an update on the ongoing construction progress at the fully permitted Johnson Camp Mine in southeast Arizona. Speaking with Proactive, Winton confirmed that construction activities are on schedule, with the company expecting to produce copper cathode by Q3 2025. Mining of mineralized material officially began in January 2025, and the extracted material is currently being stockpiled in preparation for the completion of the leach pad. The Phase-1 leach pad has been successfully completed, while Phase-2 is advancing rapidly. Once Phase-2 is in place, the company will begin installing Nuton’s advanced processing equipment, a key step toward optimizing sulfide and oxide mineralized material processing. Gunnison Copper has also completed the redesign and construction of a state-of-the-art laboratory for on-site material and process analysis. The lab is set to begin ramping up in April 2025 and will be fully commissioned once leach pad production is underway. Additionally, the company’s HR team is making significant strides in building a strong workforce, with an emphasis on local hiring. Gunnison Copper has already brought in exceptional talent, reinforcing its commitment to both operational excellence and community engagement. With these developments, Gunnison Copper remains on track to deliver sustainable copper production, leveraging innovative technologies and a highly skilled team to drive success at Johnson Camp Mine. #proactiveinvestors #gunnisoncoppercorp #tsx #gcu #otcqb #gcumf #mining #johnsoncampmine GunnisonCopper #NutonTechnology #JohnsonCamp #CriticalMinerals #MadeInAmericaCopper #HeapLeaching #MiningUpdate #RioTintoPartnership #CopperSupplyChain #Q2MiningOutlook

Proactive - Interviews for investors

Technology Minerals CEO on black mass and Leinster milestones

Technology Minerals CEO Alex Stanbury talked with Proactive's Stephen Gunnion about a milestone week for the company, highlighting significant progress in both its recycling operations and exploration asset portfolio. Stanbury discussed the first shipment of black mass from its Recyclus facility to Europe, under an agreement with Glencore. He explained that black mass—a hazardous material containing lithium, cobalt, and nickel—requires complex approvals for cross-border movement. “It’s been a lot of work in the making to get this black mass moved off-site,” Stanbury said, noting this completes a critical part of the company’s business model. He also commented on the importance of the Glencore partnership, stating that “for Glencore to have the faith to work with us…is really important.” This collaboration ensures a consistent offtake of all Recyclus production. Stanbury also confirmed Recyclus is working with Ocado, managing end-of-life batteries from their robotic systems. The company uses its proprietary LiBoxes to safely store and transport used lithium-ion batteries, providing safety and ESG compliance. “We’ve done thousands of batteries for them now and there’s an ongoing maintenance programme,” he added. Finally, Technology Minerals has completed the sale of its Leinster lithium project in Ireland, aligning with its strategy of incubating early-stage assets and moving them up the value curve. The company is now focused on its Spanish project, which benefits from EU interest in critical materials and battery manufacturing. It expects further licenses to be granted soon and aims to seek JV partners to bring the project toward feasibility and production. For more updates, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #TechnologyMinerals #Recyclus #Glencore #BlackMass #BatteryRecycling #CriticalMetals #Ocado #LithiumRecycling #LiBoxes #ESG #SustainableMining #E

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Followers	29
Posts	1687
Boards Moderated	0
Alias Born	01/02/2008

Volume:	22
Day Range:
Bid:
Ask:
Last Trade Time:	4:56:12 AM EDT
Total Trades:	9

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SCI Detailed Quote

Recent SCI News

More SCI News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SCI News

Go Ad-Free